NICE has proposed age-based CA125 thresholds to improve early ovarian cancer detection while reducing unnecessary scans in ...

Ovarian cancer reprograms the omentum to shield hidden tumors. New research suggests total omentectomy may curb recurrence and improve long-term outcomes.

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that France’s National Agency for Medicines and Health Products Safety (ANSM) has approved an updated national ...

Novel small molecule inhibitors show promising efficacy in endometrial cancer, with ongoing trials expanding treatment ...

Georgetown University's Lombardi Comprehensive Cancer Center researchers have identified a new way to reprogram T cells, ...

NP-G2-044 (Prilukae), a novel oral fascin inhibitor, has earned orphan drug designation (ODD) from the FDA for the treatment ...

A live webcast of the fireside chat can be found here and on the investor relations section of the Company’s website at https://investors.genelux.com/. Following the live webcast, an archived replay ...

Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment ...

Immunocore announces 2026 strategic priorities at 44th Annual J.P. Morgan Healthcare Conference Reaching more metastatic uveal melanoma patients ...

As of Friday, January 09, Zentalis Pharmaceuticals, Inc.’s ZNTL share price has surged by 22.18%, which has investors ...

Cannabidiol (CBD), a non-intoxicating compound in marijuana, “holds substantial promise as an anti-tumor agent” in addition to its other anti-inflammatory properties, a new scientific review ...

The third-line results build on equally compelling second-line data, where pelareorep achieved a 30% response rate, more than doubling the 13.8% benchmark for the only FDA-approved immunotherapy in ...